Items Tagged ‘nsclc’

June 22, 2018

Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer

By

An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda (pembrolizumab) plus traditional chemotherapy compared with those who received placebo plus chemotherapy. About Lung Cancer Lung cancer remains the leading cause […]

View full entry

Tags: immunotherapy, keytruda, Lung Cancer, News, nsclc, pembrolizumab, Precision Cancer Medicine, squamous non–small-cell lung cancer


June 5, 2018

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations

By

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine […]

View full entry

Tags: crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, MET exon 14 alterations, News, non-small cell lung cancer, nsclc, treatment, xalkori


January 24, 2018

FDA Broadens Gilotrif Indication to Previously Untreated, Metastatic NSCLC with Other Non-Resistant EGFR Mutations

By

CancerConnect News: The Food and Drug Administration (FDA) has granted approval to Gilotrif®  (afatinib) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Lung cancer remains the leading cause of cancer death […]

View full entry

Tags: afatinib, EGFR, gilotrif, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Precision Cancer Medicine


January 17, 2018

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer

By

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical trial evaluated Keytruda in combination with Alimta (pemetrexed) and cisplatin or carboplatin chemotherapy for the first-line treatment of patients with NSCLC. Interim results […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, non-squamous, nsclc, PD1 Inhibitor, pembrolizumab, Precision Cancer Medicine


January 15, 2018

Tagrisso Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients

By

CancerConnect News: Tagrisso (osimertinib) improves progression-free survival compared to standard first line therapy in Asian patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). 1,2 Lung cancer is the number one cause of cancer-related deaths in the United States.  Research identifying specific molecular and genetic components of a patient’s cancer cells has led to […]

View full entry

Tags: EGFR-TKI, first-line treatment, Lung Cancer, News, non-small cell lung cancer, nsclc, osmertinib, tagrisso


November 13, 2017

Alcensa Precision Medicine Approved for (ALK) Positive Non-Small Cell Lung Cancer

By

The Food and Drug Administration granted regular approval to Alcensa (alectinib), for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. In December 2015, Alcensa received accelerated approval for treatment of patients with ALK-positive metastatic NSCLC whose disease progressed on or who were intolerant […]

View full entry

Tags: Alcensa, alectinib, alk, anaplastic lymphoma kinase, crizotinib, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, positive metastatic, Precision Cancer Medicine, xalkori


October 4, 2017

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), which is […]

View full entry

Tags: 2016, advanced, ESMO, keytruda, Lung Cancer, News, Non-Hodgkin's Lymphoma, nsclc, opdivo, PD-1, pembrolizumab, Tecentriq


September 21, 2017

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain

By

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC) that has spread to the brain in anaplastic lymphoma kinase (ALK) gene positive NSCLC. Non-squamous NSCLC is the most […]

View full entry

Tags: Alecensa, alectinib, alk, anaplastic lymphoma kinase, brain metastases, crizotinib, gene positive NSCLC, Lung Cancer - Non-Small Cell, News, non small cell lung caner, nsclc, Precision Cancer Medicine


March 11, 2015

Novel PD-1 Inhibitor Opdivo Approved for Treatment of Lung Cancer

By

The Food and Drug Administration has expanded approval of the PD-1 inhibitor Opdivo® (nivolumab) to include treatment of patients who have metastatic squamous non–small cell lung cancer (NSCLC) that progresses following treatment with platinum-based chemotherapy. Nivolumab belongs to a new class of medicines called PD-1 inhibitors that have generated great excitement for their ability to […]

View full entry

Tags: FDA approval, immune response, Lung Cancer, Lung Cancer - Non-Small Cell, metastatic squamous non-small cell lung cancer, nsclc, opdivo, PD-1 inhibitor, Recurrent Lung Cancer - Non-Small Cell